Quarterly report [Sections 13 or 15(d)]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)

v3.25.1
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Research and development expense $ (1,588,540) $ (1,539,070)
General and administrative expense (1,258,450) (1,270,528)
Net Loss (2,834,405) (2,726,381)
Reportable Segment, Aggregation before Other Operating Segment [Member]    
Segment Reporting Information [Line Items]    
Preclinical, clinical trial and other costs 1,197,035 1,031,280
Administrative and facilities expense [1] 584,671 751,697
Other income, net (12,585) (83,217)
Net Loss 2,834,405 2,726,381
Reportable Segment, Aggregation before Other Operating Segment [Member] | Employees [Member]    
Segment Reporting Information [Line Items]    
Research and development expense [2] 391,505 507,790
General and administrative expense [3] $ 673,779 $ 518,831
[1] Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
[2] Research and development personnel costs include employee stock-based compensation expense of $46,720 and $31,121 for the three months ended March 31, 2025 and 2024, respectively.
[3] General and administrative personnel costs include employee stock-based compensation expense of $122,655 and $38,871 for the three months ended March 31, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC.